-
Product Insights
NewNet Present Value Model: Replimune Ltd’s Vusolimogene Oderparepvec
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
Innovation and Patenting activity of Replimune Group Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Replimune Group Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewNet Present Value Model: Poseida Therapeutics Inc’s PMUC1CALLO-1
Empower your strategies with our Net Present Value Model: Poseida Therapeutics Inc's PMUC1CALLO-1 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Asundexian in Acute Ischemic Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Asundexian in Acute Ischemic Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Asundexian in Acute Ischemic Stroke Drug Details: Asundexian is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RP-2 in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-2 in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RP-2 in Nasopharyngeal Cancer Drug Details: RP-2 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HHCYH-33 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HHCYH-33 in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HHCYH-33 in Cervical Cancer Drug Details: HHCYH-33 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMS-001 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMS-001 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Saracatinib Difumarate in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Saracatinib Difumarate in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Saracatinib Difumarate in Fibrodysplasia Ossificans Progressiva (Myositis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Metastatic Melanoma Drug Details: RP-1 is under development...